Cleveland Biolabs Inc. (CBLI) Release: Cancer Prevention Research Publishes Preclinical Studies on Suppression of Breast Cancer Tumor Formation and Progression Using CBL0137  
7/2/2012 9:26:41 AM

BUFFALO, N.Y., July 2, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI)and its subsidiary, Incuron, LLC, announced today that a study demonstrating that CBL0137 counteracts tumor formation in a mouse spontaneous breast cancer model was published online in Cancer Prevention Research, a peer-reviewed publication of the American Association for Cancer Research. The paper was co-authored by scientists at Roswell Park Cancer Institute and Cleveland BioLabs.